Prevalence and predictors of high-risk human papillomavirus infection in a population-based sample of women in rural Uganda

International Journal of STD and AIDS

Volumn 19, Issue 9, 2008, Pages 605-610

  Asiimwe, Stephen ^a,b   Whalen, Christopher C ^a   Tisch, Daniel J ^a   Tumwesigye, Elioda ^b   Sethi, Ajay K ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Kabwohe Clinical Research Center (KCRC)   (Uganda)

Author keywords

High risk HPV; HIV; Human papillomavirus (HPV); Self collected vaginal sample; Uganda

Indexed keywords

DNA HYBRID; VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RURAL AREA; UGANDA; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; AGE FACTORS; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK FACTORS; RURAL POPULATION; SEXUALLY TRANSMITTED DISEASES, VIRAL; UGANDA; YOUNG ADULT;

EID: 50849094245     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2008.008025     Document Type: Article

References (40)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9
2. Chirenje ZM. HIV and cancer of the cervix. Best Pract Res Clin Obstet Gynaecol 2005;19:269-76
3. Sun CA, Liu JF, Wu DM, Nieh S, Yu CP, Chu TY. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int J Gynaecol Obstet 2002;76:41-7
4. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992;79:328-37
5. Mayaud P, Gill DK, Weiss HA, et al. The interrelation of HIV, cervical human papillomavirus, and neoplasia among antenatal clinic attenders in Tanzania. Sex Transm Infect 2001;77:248-54
6. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001;183:8-15
7. Wang SS, Schiffman M, Herrero R, et al. Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10,000 women in Costa Rica. Br J Cancer 2004;91:1269-74
8. Parkin DM, Wabinga H, Nambooze S, Wabwire-Mangen F. AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS 1999;13:2563-70
9. International Agency for Research on Cancer (IARC). GLOBOCAN 2002 database: summary table by population. 2005
10. Chirenje ZM, Rusakaniko S, Kirumbi L, et al. Situation analysis for cervical cancer diagnosis and treatment in east, central and southern African countries. Bull World Health Organ 2001;79:127-32
11. Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005;23:2388- 94
12. Tumwesigye E, Muganzi E, Tumwebaze N. Bushenyi District Full Access home based HIV counselling and testing program annual report 2006. 15 February 2006
13. Serwadda D, Wawer MJ, Shah KV, et al. Use of a hybrid capture assay of self-collected vaginal swabs in rural Uganda for detection of human papillomavirus. J Infect Dis 1999;180:1316-9
14. Obiso R, Lorincz A. Digene Corporation. Pharmacogenomics 2004;5:129-32
15. Lack N, West B, Jeffries D, et al. Comparison of non-invasive sampling methods for detection of HPV in rural African women. Sex Transm Infect 2005;81:239-41
16. Safaeian M, Kiddugavu M, Gravitt PE, et al. Comparability of self-collected vaginal swabs and physician-collected cervical swabs for detection of human papillomavirus infections in Rakai, Uganda. Sex Transm Dis 2007;34:429-36
17. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8
18. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8
19. Wheeler CM, Parmenter CA, Hunt WC, et al. Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center. Sex Transm Dis 1993;20:286-9
20. Winer RL, Koutsky LA. Human papillomavirus through the ages. J Infect Dis 2005;191:1787-9
21. Blossom DB, Beigi RH, Farrell JJ, et al. Human papillomavirus genotypes associated with cervical cytologic abnormalities and HIV infection in Ugandan women. J Med Virol 2007;79:758-65
22. Kahn JA, Rosenthal SL, Succop PA, Ho GY, Burk RD. Mediators of the association between age of first sexual intercourse and subsequent human papillomavirus infection. Pediatrics 2002;109:E5
23. Giuliano AR, Sedjo RL, Roe DJ, et al. Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes Control 2002;13:839-46
24. Franco EL, Villa LL, Ruiz A, Costa MC. Transmission of cervical human papillomavirus infection by sexual activity: differences between low and high oncogenic risk types. J Infect Dis 1995;172:756-63
25. Kjaer SK, van den Brule AJ, Bock JE, et al. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev 1997;6:799-805
26. Howley PM, Schlegel R. The human papillomaviruses. An overview. Am J Med 1988;85:155-8
27. Moodley M, Moodley J, Chetty R, Herrington CS. The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. Int J Gynecol Cancer 2003;13:103-10
28. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002;29:725-35
29. Manhart LE, Holmes KK, Koutsky LA, et al. Human papillomavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis 2006;33:502-8
30. Scheurer ME, Tortolero-Luna G, dler-Storthz K. Human papillomavirus infection: biology, epidemiology, and prevention. Int J Gynecol Cancer 2005;15:727-46
31. Ahdieh L, Munoz A, Vlahov D, Trimble CL, Timpson LA, Shah K. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol 2000;151:1148-57
32. Ahdieh L, Klein RS, Burk R, et al. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J Infect Dis 2001;184:682-90
33. Kirby TO, Allen ME, Alvarez RD, Hoesley CJ, Huh WK. High-risk human papillomavirus and cervical intraepithelial neoplasia at time of atypical squamous cells of undetermined significance cytologic results in a population with human immunodeficiency virus. J Low Genit Tract Dis 2004;8:298-303
34. Kjaer SK, Svare EI, Worm AM, Walboomers JM, Meijer CJ, van den Brule AJ. Human papillomavirus infection in Danish female sex workers. Decreasing prevalence with age despite continuously high sexual activity. Sex Transm Dis 2000;27:438-45
35. Palefsky JM, Holly EA. Chapter 6: Immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr 2003;31:41-6
36. The FUTURE II study group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27
37. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-8
38. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693-702
39. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56:1-24
40. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85